Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) CEO Keith Michael Gottesdiener sold 9,288 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $30.06, for a total value of $279,197.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Keith Michael Gottesdiener also recently made the following trade(s):

  • On Wednesday, February 27th, Keith Michael Gottesdiener sold 2,449 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.04, for a total value of $73,567.96.
  • On Tuesday, February 19th, Keith Michael Gottesdiener sold 12,920 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.02, for a total value of $387,858.40.
  • On Wednesday, February 13th, Keith Michael Gottesdiener sold 3,934 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total value of $118,020.00.
  • On Wednesday, January 23rd, Keith Michael Gottesdiener sold 15,779 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.05, for a total value of $474,158.95.
  • On Friday, January 18th, Keith Michael Gottesdiener sold 10,115 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.01, for a total value of $303,551.15.
  • On Wednesday, January 16th, Keith Michael Gottesdiener sold 662 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total value of $19,860.00.

NASDAQ RYTM opened at $30.02 on Friday. The stock has a market capitalization of $1.01 billion, a P/E ratio of -12.56 and a beta of 1.43. Rhythm Pharmaceuticals Inc has a twelve month low of $16.80 and a twelve month high of $37.23.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its earnings results on Friday, March 8th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.17). Analysts forecast that Rhythm Pharmaceuticals Inc will post -2.17 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in RYTM. Great West Life Assurance Co. Can acquired a new position in shares of Rhythm Pharmaceuticals during the fourth quarter valued at approximately $68,000. Legal & General Group Plc raised its holdings in shares of Rhythm Pharmaceuticals by 46.6% during the third quarter. Legal & General Group Plc now owns 2,675 shares of the company’s stock valued at $78,000 after acquiring an additional 850 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its holdings in shares of Rhythm Pharmaceuticals by 424.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,020 shares of the company’s stock valued at $135,000 after acquiring an additional 4,062 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Rhythm Pharmaceuticals by 110.5% during the second quarter. Bank of America Corp DE now owns 6,251 shares of the company’s stock valued at $195,000 after acquiring an additional 3,282 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new position in shares of Rhythm Pharmaceuticals during the third quarter valued at approximately $280,000. 92.16% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently weighed in on the company. ValuEngine raised Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday. Zacks Investment Research cut Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. LADENBURG THALM/SH SH assumed coverage on Rhythm Pharmaceuticals in a report on Wednesday. They issued a “buy” rating and a $43.00 price target for the company. Cowen reaffirmed a “buy” rating and issued a $40.00 price target on shares of Rhythm Pharmaceuticals in a report on Friday, March 8th. Finally, BidaskClub cut Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $39.33.

COPYRIGHT VIOLATION WARNING: “Keith Michael Gottesdiener Sells 9,288 Shares of Rhythm Pharmaceuticals Inc (RYTM) Stock” was posted by Marea Informative and is owned by of Marea Informative. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.mareainformativa.com/news/2019/03/17/keith-michael-gottesdiener-sells-9288-shares-of-rhythm-pharmaceuticals-inc-rytm-stock.html.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.

Featured Article: What are earnings reports?

Insider Buying and Selling by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.